Corvus Pharmaceuticals, Inc.
CRVS
$13.33
-$0.60-4.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -31.16% | -11.13% | -21.31% | -26.99% | -152.64% |
| Total Depreciation and Amortization | 17.24% | 11.54% | -7.14% | -3.45% | 31.82% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 8.38% | 60.00% | 81.49% | 258.77% | 97.03% |
| Change in Net Operating Assets | -1,812.28% | -94.74% | 297.09% | -119.01% | 1,803.29% |
| Cash from Operations | -48.43% | -12.87% | 3.92% | -65.59% | 30.09% |
| Capital Expenditure | -539.56% | -264.00% | -- | 100.00% | -213.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 96.28% | -1,427.42% | 516.54% | 87.03% | -571.79% |
| Cash from Investing | 95.88% | -1,431.31% | 515.58% | 87.10% | -578.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.91% | 953,630.00% | -94.44% | -98.99% | 12,720.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.91% | 953,630.00% | -94.44% | -98.99% | 12,720.79% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -159.67% | 1,978.76% | 114.45% | -222.00% | 359.08% |